A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
To assess the effectiveness of latanoprost 0.005% ophthalmic solution dosed once-daily and
timolol 0.5% dosed twice-daily in paediatric subjects of 18 years of age or under who are
diagnosed with glaucoma.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.